Skip to main content

Advertisement

Table 1 Patient characteristics

From: Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

  Dormant, n (%) Resistant, n (%) Total, n p valuea
Total no. of patients 42 20 62  
Total no. of samples 111 56 167  
Age at diagnosis
 Mean 75 72   
 Range 53–87 56–89   
Tumour grade     0.39
 1 6 (14.3) 1 (5.0) 7  
 2 27 (64.3) 10 (50.0) 37  
 3 8 (19.0) 6 (30.0) 14  
 NA 1 (2.4) 3 (15.0) 4  
Tumour size     0.71
 T1 5 (11.9) 4 (20.0) 9  
 T2 19 (45.2) 9 (45.0) 28  
 T3 2 (4.8) 2 (10.0) 4  
 T4 11 (26.2) 4 (20.0) 15  
 NA 5 (11.9) 1 (5.0) 6  
Nodal status     0.36
 N0 27 (64.3) 11 (55.0) 38  
 N1 8 (19.0) 7 (35.0) 15  
 N2 1 (2.4) 1 (5.0) 2  
 N3 1 (2.4) 0 1  
 NX 1 (2.4) 0 1  
 NA 4 (9.5) 1 (5.0) 5  
Metastasis status     1.00
 M0 34 (80.9) 18 (90.0) 56  
 M1 2 (4.8) 0 2  
 MX 1 (2.4) 1 (5.0) 2  
 NA 5 (11.9) 1 (5.0) 6  
ER score (Allred)     0.18
 6 1 (2.4) 0 1  
 7 6 (14.3) 6 (30.0) 12  
 8 35 (83.3) 14 (70.0) 49  
HER status     0.69
 Negative 35 (83.3) 12 (60.0) 47  
 Positive 6 (14.3) 3 (15.0) 9  
 NA 1 (2.4) 5 (25.0) 6  
Histological type     0.73
 IDC (no special type) 18 (42.9) 6 (30) 24  
 ILC 8 (19.0) 4 (20) 12  
 Mucinous 1 (2.4) 0 1  
 NA 15 (35.7) 10 (50) 25  
Molecular subtypeb     1.00
 Luminal A 21 (50.0) 9 (45.0) 30  
 Luminal B 20 (47.6) 9 (45.0) 29  
 HER2 enriched 0 1 (5.0) 1  
 Basal-like 0 0 0  
 Normal-like 0 0 0  
 NA 1 (2.4) 1 (5.0) 2  
  1. ER oestrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NA not available
  2. aFisher exact test (p < 0.05, two-tailed)
  3. bAt diagnosis by PAM50 (genefu)